June 30th 2025
The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.
Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.
HCT Effective for Patients With Non-Hodgkin Lymphoma Regardless of Age
Study Documents Chronic Pain Associated With Sickle Cell Disease